P601 Development and validation of dried blood spot sampling as a tool to identify the best time point to measure predictive ustekinumab serum concentrations in patients with Crohn’s disease

Nathalie Van den Berghe(KU Leuven), Debby Thomas(KU Leuven), Marc Ferrante(Universitair Ziekenhuis Leuven), Bram Verstockt(Universitair Ziekenhuis Leuven), Vera Ballet(KU Leuven), Ann Gils(KU Leuven), Eline Vandeput(KU Leuven), Séverine Vermeire(KU Leuven)
Journal of Crohn s and Colitis
January 1, 2020
10.1093/ecco-jcc/jjz203.729
Cited by 3

Related Papers

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
|Journal of Crohn s and Colitis|2019|1.4k